Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00793650 · ClinicalTrials.gov registry record · Phase 1
Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
A Phase 1 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT00793650 is a Phase 1 study that was terminated before completion, run by Emory University. The registered enrollment target is 39 participants.
The verdict
NCT00793650, a Phase 1 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the safety of melphalan and autologous PBSCT (peripheral blood stem cell transplantation - stem cells that come from your own body) in combination with bortezomib, a new FDA approved drug used to treat myeloma.
Interventions
- DRUG Melphalan
- DRUG Bortezomib
- PROCEDURE Autologous PBSC Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2005-05 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00793650
The ClinicalTrials.gov registry entry for NCT00793650 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Melphalan is the first listed.
NCT00793650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00793650 about?
NCT00793650 is a clinical study titled "Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study". The goal of this study is to evaluate the safety of melphalan and autologous PBSCT (peripheral blood stem cell transplantation - stem cells that come from your own body) in combination with bortezomib, a new FDA approved drug used to treat myeloma.
What is the current status of trial NCT00793650?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2005-05. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00793650?
The interventions under investigation include: Melphalan (DRUG), Bortezomib (DRUG), Autologous PBSC Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00793650?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.